(BIS)UREA AND (BIS)THIOREA COMPOUNDS AS EIPGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS
申请人:Casero Robert A.
公开号:US20120322877A1
公开(公告)日:2012-12-20
The invention provides for novel (bis)urea and (bis)thiourea compounds which are inhibitors of lysine-specific demethylase 1 (LSD1). Such compounds may be used to treat disorders, including cancer.
[EN] (BIS) UREA AND (BIS) THIOUREA COMPOUNDS AS EPIGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS<br/>[FR] COMPOSÉS (BIS)URÉE ET (BIS)THIOURÉE EN TANT QUE MODULATEURS ÉPIGÉNIQUES DE LA DÉMÉTHYLASE 1 SPÉCIFIQUE À LA LYSINE ET MÉTHODES DE TRAITEMENT DE TROUBLES
申请人:UNIV JOHNS HOPKINS
公开号:WO2011022489A2
公开(公告)日:2011-02-24
The invention provides for novel (bis)urea and (bis)thiourea compounds which are inhibitors of lysine- specific demethylase 1 (LSD1). Such compounds may be used to treat disorders, including cancer.
作者:Bo Wang、Boobalan Pachaiyappan、Jordon D. Gruber、Michael G. Schmidt、Yong-Mei Zhang、Patrick M. Woster
DOI:10.1021/acs.jmedchem.5b01912
日期:2016.4.14
Antibiotic resistance is a growing threat to human health exacerbated by a lack of new antibiotics. We now describe a series of substituted diamines that produce rapid bactericidal activity against both Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus and stationary-phase bacteria. These compounds reduce biofilm formation and promote biofilm dispersal